Back
Results - Announcements
Gennex Laboratories Ltd consolidated sales down 34.65% on year in Q2FY2026, net profit saw a marginal increase of 4.71%
14-Aug-2026, 09:36
Gennex Laboratories Ltd share price rallied 13.30% to Rs 10.82 after the company's net profit inched up 4.71% to Rs 4.67 crore, while revenue from operations plunged by 34.65% to Rs 39.84 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.59%. It has marginally improved by 0.05% over last one week and moving up by 10.53% in last one month while the market capitalization of Gennex Laboratories Ltd has significantly gained 20.89% and 13.65% in the same period respectively. Profit before tax (PBT) of Gennex Laboratories Ltd stood at Rs 4.92 crore in Q2 FY26, nosediving by 16.18% year-on-year, and easing 5.35% quarter-on-quarter. EBITDA came in at Rs 2 crore, tumbling by 15.05% YoY and tanking 48.14% sequentially. Total expenses slumped by 35.34% to Rs 36.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 29.67 crore, slumping by 46.34% YoY, while employee benefits expense was at Rs 1.98 crore, soaring 69.23% YoY. For the TTM ended FY26, revenue from operations soared by 59.04% to Rs 137.9 crore, while net profit saw a strong growth of 37.48% to Rs 18.12 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 2056% to Rs 6.29 crore, and PBT jumped 29.78% to Rs 21.4 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 10.8 crore in FY26, as against Rs 46.69 crore in FY25. Gennex Laboratories Ltd crashed 23.29% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.
Gennex Laboratories Ltd share price rallied 13.30% to Rs 10.82 after the company's net profit inched up 4.71% to Rs 4.67 crore, while revenue from operations plunged by 34.65% to Rs 39.84 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.59%. It has marginally improved by 0.05% over last one week and moving up by 10.53% in last one month while the market capitalization of Gennex Laboratories Ltd has significantly gained 20.89% and 13.65% in the same period respectively. Profit before tax (PBT) of Gennex Laboratories Ltd stood at Rs 4.92 crore in Q2 FY26, nosediving by 16.18% year-on-year, and easing 5.35% quarter-on-quarter. EBITDA came in at Rs 2 crore, tumbling by 15.05% YoY and tanking 48.14% sequentially. Total expenses slumped by 35.34% to Rs 36.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 29.67 crore, slumping by 46.34% YoY, while employee benefits expense was at Rs 1.98 crore, soaring 69.23% YoY. For the TTM ended FY26, revenue from operations soared by 59.04% to Rs 137.9 crore, while net profit saw a strong growth of 37.48% to Rs 18.12 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 2056% to Rs 6.29 crore, and PBT jumped 29.78% to Rs 21.4 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 10.8 crore in FY26, as against Rs 46.69 crore in FY25. Gennex Laboratories Ltd crashed 23.29% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.